Botanix Pharmaceuticals Limited (ASX:BOT)
Australia · Delayed Price · Currency is AUD | Market Cap | 24.86M -90.3% |
| Revenue (ttm) | 33.80M +483.9% |
| Net Income | -69.77M |
| EPS | -0.03 |
| Shares Out | 2.76B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,225,473 |
| Open | 0.0090 |
| Previous Close | 0.0090 |
| Day's Range | 0.0080 - 0.0090 |
| 52-Week Range | 0.0080 - 0.1500 |
| Beta | 0.92 |
| Analysts | Buy |
| Price Target | 0.44 (+4,788.89%) |
| Earnings Date | Oct 26, 2026 |
About Botanix Pharmaceuticals
Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase ... [Read more]
Financial Performance
In fiscal year 2026, Botanix Pharmaceuticals's revenue was 33.80 million, an increase of 483.87% compared to the previous year's 5.79 million. Losses were -69.77 million, -19.25% less than in 2025.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BOT stock is "Buy." The 12-month stock price target is $0.44, which is an increase of 4,788.89% from the latest price.
News
Botanix Pharmaceuticals Earnings Call Transcript: Q1 2027
Q1 FY2027 Sofdra prescriptions grew, but lower prior authorization activity reduced gross-to-net to 21% and kept net revenue flat at $10.1 million. A major cost reset targets ~50% lower expenses while retaining ~75% of revenue-generating ability, alongside strategic alternatives and portfolio growth.
Botanix Pharmaceuticals Earnings release: Q1 2027
Botanix Pharmaceuticals released its Q1 2027 earnings on October 26, 2026, summarizing the period's financial results.
Botanix Pharmaceuticals Slides: Q1 2027
Botanix Pharmaceuticals has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on October 26, 2026.
Botanix Pharmaceuticals Annual report: H2 2026
Botanix Pharmaceuticals has published its H2 2026 annual report on August 25, 2026.
Botanix Pharmaceuticals Earnings Call Transcript: Q4 2026
Q4 saw a 45% net revenue increase to $10.1M, with prescription shipments up 25% and gross-to-net yield rising to 22%. Cost-saving initiatives, strong IP, and a scalable platform position the business for continued growth and strategic expansion.
Botanix Pharmaceuticals Earnings release: Q4 2026
Botanix Pharmaceuticals released its Q4 2026 earnings on July 26, 2026, summarizing the period's financial results.
Botanix Pharmaceuticals Slides: Q4 2026
Botanix Pharmaceuticals has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on July 26, 2026.
Botanix Pharmaceuticals Earnings Call Transcript: Q3 2026
Sofdra prescriptions and revenue continue to grow, with March 2026 setting a new record. Strong cash position, cost discipline, and a new API supplier are expected to drive future margin expansion and mitigate tariff risks. The platform is well-positioned for additional product launches.
Botanix Pharmaceuticals Earnings release: Q3 2026
Botanix Pharmaceuticals released its Q3 2026 earnings on April 28, 2026, summarizing the period's financial results.
Botanix Pharmaceuticals Slides: Q3 2026
Botanix Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on April 28, 2026.
Botanix Pharmaceuticals price target lowered to A$1 from A$2 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Botanix Pharmaceuticals (BXPHF) to A$1 from A$2 and keeps a Buy rating on the shares. The firm cites the ongoing equity raise…
Botanix Pharmaceuticals Earnings Call Transcript: H1 2026
Sofdra prescriptions and revenue surged in the first half of FY2026, driven by strong sales force execution and a scalable fulfillment platform. A major capital raise is underway to fund growth, reduce COGS, and support expansion, with profitability targeted as platform efficiencies scale.
Botanix Pharmaceuticals Quarterly report: H1 2026
Botanix Pharmaceuticals has published its H1 2026 quarterly earnings report on March 2, 2026.
Botanix Pharmaceuticals Slides: H1 2026
Botanix Pharmaceuticals has posted slides in relation to its H1 2026 quarterly earnings report, which was published on March 2, 2026.
Botanix Pharmaceuticals Earnings Call Transcript: Q2 2026
Revenue and prescriptions for Sofdra grew strongly, with net revenue up 28% quarter-over-quarter and gross-to-net yield improving to 24%. Sales force expansion and a unique fulfillment platform are driving growth, while cost-saving initiatives and high physician intent to prescribe support a positive outlook.
Botanix Pharmaceuticals Earnings release: Q2 2026
Botanix Pharmaceuticals released its Q2 2026 earnings on January 26, 2026, summarizing the period's financial results.
Botanix Pharmaceuticals Slides: Q2 2026
Botanix Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on January 26, 2026.